The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Open accessAbstract
The adoptive transfer of T cells redirected to tumor-associated antigens via transgenic expression of chimeric antigen receptors (CARs) has produced tumor responses, even in patients with refractory diseases. To target pancreatic cancer, we generated CAR T cells directed against prostate stem cell antigen (PSCA) and demonstrated specific tumor lysis. However, pancreatic tumors employ immune evasion strategies such as the production of inhibitory cytokines, which limit CAR T cell persistence and function. Thus, to protect our cells from the immunosuppressive cytokine IL-4, we generated an inverted cytokine receptor in which the IL-4 receptor exodomain was fused to the IL-7 receptor endodomain (4/7 ICR). Transgenic expression of this molecule in CAR-PSCA T cells should invert the inhibitory effects of tumor-derived IL-4 and instead promote T cell proliferation. We now demonstrate the suppressed activity of CAR T cells in tumor-milieu conditions and the ability of CAR/ICR T cells to thrive in an IL-4-rich microenvironment, resulting in enhanced antitumor activity. Importantly, CAR/ICR T cells remained both antigen and cytokine dependent. These findings support the benefit of combining the 4/7 ICR with CAR-PSCA to treat pancreatic cancer, a PSCA-expressing tumor characterized by a dense immunosuppressive environment rich in IL-4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Self-citationBeatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Lin, J.-X., Migone, T.-S., Tseng, M., Friedmann, M., Weatherbee, J. A., Zhou, L., Yamauchi, A., Bloom, E. T., Mietz, J., John, S., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90141-8 · Cited by 752
Gocheva, V., Wang, H.-W., Gadea, B. B., Shree, T., Hunter, K. E., Garfall, A. L., Berman, T., & Joyce, J. A. (2010) · Genes & Development · doi:10.1101/gad.1874010 · Cited by 740
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Self-citationLogsdon, C. D., Simeone, D. M., Binkley, C. E., Arumugam, T., Greenson, J. K., Giordano, T. J., Misek, D. E., Kuick, R. D., & Hanash, S. (2003) · PubMed · Cited by 546
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
Self-citationGu, Z., Thomas, G., Yamashiro, J., Shintaku, I. P., Dorey, F., Raitano, A., Witte, O., Said, J., Loda, M., & Reiter, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203426 · Cited by 436
Erkan, M., Michalski, C. W., Rieder, S., Reiser–Erkan, C., Abiatari, I., Kolb, A., Giese, N. A., Esposito, I., Friess, H., & Kleeff, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.05.006 · Cited by 424
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes
Straathof, K. C. M., Bollard, C. M., Popat, U., Huls, M. H., Lopez, T., Morriss, M. C., Gresik, M. V., Gee, A. P., Russell, H. V., Brenner, M. K., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2975 · Cited by 353
Self-citationNishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier-Hayes, L., Savoldo, B., & Dotti, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0697 · Cited by 331
Bollard, C. M., Rössig, C., Calonge, M. J., Huls, M. H., Wagner, H.-J., Massague, J., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2002) · Blood · doi:10.1182/blood.v99.9.3179 · Cited by 316
Self-citationThe biology of Stat4 and Stat6
Wurster, A. L., Tanaka, T., & Grusby, M. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203485 · Cited by 309
Ochi, A., Nguyen, A. H., Bedrosian, A. S., Mushlin, H. M., Zarbakhsh, S., Barilla, R., Zambirinis, C. P., Fallon, N. C., Rehman, A., Pylayeva-Gupta, Y., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111706 · Cited by 304
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Song, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
Systemic and local immunosuppression in pancreatic cancer patients.
von Bernstorff, W., Voss, M., Freichel, S., Schmid, A., Vogel, I., Jöhnk, C., Henne‐Bruns, D., Kremer, B., & Kalthoff, H. (2001) · PubMed · Cited by 279
Improving T Cell Therapy for Cancer
Leen, A. M., Rooney, C. M., & Foster, A. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141527 · Cited by 240
Self-citationAbate-Daga, D., Lagisetty, K. H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., Burns, W. R., Miermont, A. M., Teper, Y., Rudloff, U., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.209 · Cited by 191
Prosser, M. E., Brown, C. E., Shami, A. F., Forman, S. J., & Jensen, M. C. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.03.023 · Cited by 184
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
Leen, A. M., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J., Yanagisawa, R., Anurathapan, U., Rendon, D., Heslop, H. E., Rooney, C. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.47 · Cited by 184
Self-citationUpdate on the management of pancreatic cancer: Surgery is not enough
Ansari, D., Gustafsson, A., & Andersson, R. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i11.3157 · Cited by 180
Barata, J. T., Cardoso, A. A., Nadler, L. M., & Boussiotis, V. A. (2001) · Blood · doi:10.1182/blood.v98.5.1524 · Cited by 173
Prostate Stem Cell Antigen: A Jekyll and Hyde Molecule?
Saeki, N., Gu, J., Yoshida, T., & Wu, X. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3169 · Cited by 170
Prokopchuk, O., Liu, Y., Henne-Bruns, D., & Kornmann, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602416 · Cited by 159
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03912.x · Cited by 157
Chmielewski, M. M., Hahn, O., Rappl, G., Nowak, M. A., Schmidt‐Wolf, I. G. H., Hombach, A. A., & Abken, H. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.037 · Cited by 154
Distinct Regions of the Interleukin-7 Receptor Regulate Different Bcl2 Family Members
Jiang, Q., Li, W., Hofmeister, R., Young, H. A., Hodge, D. R., Keller, J. R., Khaled, A. R., & Durum, S. K. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.14.6501-6513.2004 · Cited by 146
Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies
Rucki, A. A., & Zheng, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2237 · Cited by 133
Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells
Anurathapan, U., Chan, R. C., Hindi, H. F., Mucharla, R., Bajgain, P., Hayes, B. C., Fisher, W. E., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.262 · Cited by 128
Self-citationvan Roon, J. A. G., Glaudemans, K. A. F. M., Bijlsma, J. W. J., & Lafeber, F. P. J. G. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.2.113 · Cited by 127
Lee, L., Axtell, R. C., Tu, G. H., Logronio, K. A., Dilley, J., Yu, J., Rickert, M., Han, B., Evering, W., Walker, M. G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002400 · Cited by 119
Maliar, A., Servais, C., Waks, T., Chmielewski, M. M., Lavy, R., Altevogt, P., Abken, H., & Eshhar, Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.017 · Cited by 98
Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer
Wente, M. N., Jain, A., Kono, E. A., Berberat, P. O., Giese, T., Reber, H. A., Frieß, H., chler, M. W. B., Reiter, R. E., & Hines, O. J. (2005) · Pancreas · doi:10.1097/01.mpa.0000173459.81193.4d · Cited by 94
Genetic Manipulation of Tumor-specific Cytotoxic T Lymphocytes to Restore Responsiveness to IL-7
Vera, J. F., Hoyos, V., Savoldo, B., Quintarelli, C., Attianese, G. M. P. G., Leen, A. M., Liu, H., Foster, A. E., Heslop, H. E., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.34 · Cited by 94
Self-citationHumanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing Tumors
Leyton, J. V., Olafsen, T., Lepin, E. J., Hahm, S., Bauer, K. B., Reiter, R. E., & Wu, A. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5093 · Cited by 73
Engineered T cells for pancreatic cancer treatment
Katari, U. L., Keirnan, J. M., Worth, A. C., Hodges, S. E., Leen, A. M., Fisher, W. E., & Vera, J. F. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00344.x · Cited by 61
Self-citationLacuesta, K., Buza, E. L., Hauser, H., Granville, L. A., Pulè, M. A., Corboy, G., Finegold, M. J., Weiss, H. L., Chen, S. Y., Brenner, M. K., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000192104.24583.ca · Cited by 44
Self-citationSeatbelts in CAR therapy: How Safe Are CARS?
Minagawa, K., Zhou, X., Mineishi, S., & Stasi, A. D. (2015) · Pharmaceuticals · doi:10.3390/ph8020230 · Cited by 43
Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors
Leyton, J. V., Olafsen, T., Sherman, M. A., Bauer, K. B., Aghajanian, P., Reiter, R. E., & Wu, A. M. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn055 · Cited by 43
Wolpin, B. M., O'Reilly, E. M., Ko, Y.-J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt066 · Cited by 35
Antonarakis, E. S., Carducci, M. A., Eisenberger, M. A., Denmeade, S. R., Slovin, S. F., Jelaca-Maxwell, K., Vincent, M. E., Scher, H. I., & Morris, M. J. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1759-9 · Cited by 22
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Metadata
- Authors
- Mohammed, S., Sukumaran, S., Bajgain, P., Watanabe, N., Heslop, H. E., Rooney, C. M., Brenner, M. K., Fisher, W. E., Leen, A. M., & Vera, J. F.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 25
- Issue
- 1
- Pages
- 249-258
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2569710884
- Cited by
- 281
- References
- 52
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.